Jacob Teitelbaum, MD

New research published in Jama Network Open shows that 54% of people with COVID-19 still have persistent post-COVID symptoms at 6 months including: brain fog (23.8%), anxiety (30%), disordered sleep (27%), depression (20%), joint pain (10%), fatigue or muscle weakness (38%), and flu-like symptoms (10%). The study looked at 57 studies with 250,351 COVID-19 survivors.

"The burden of poor health in COVID-19 survivors is overwhelming...One's battle with COVID doesn't end with recovery from the acute infection," was the conclusion of researchers at Penn State College of Medicine in an accompanying news release.

According to chronic fatigue/fibromyalgia researcher and clinician Jacob Teitelbaum, MD, the disabling effects of 'long COVID' indicate what Dr. Fauci has called post-viral syndrome, which mirrors Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME).

"The wide range of seemingly unconnected physical and mental symptoms present in long COVID are the same as those found in CFS and its painful cousin fibromyalgia. They're biproducts of a critical energy crisis in the body connected to hypothalamic suppression. In other words, a circuit breaker in the brain shuts down as a protective response, and until it's rebooted patients will suffer from a plethora of disabling symptoms."

"As with post-viral Chronic Fatigue Syndrome, long COVID is a complex syndrome that requires a multi-pronged treatment approach. Fortunately, the NIH has announced an allocation over the next four years of $1.15B for research on the prolonged health consequences of COVID-19 infection. This is 25 times the past annual government funding for fibromyalgia research, which until now was considered a 'Cinderella stepchild' disease mainly contracted by women," says Dr. Teitelbaum, whose landmark double-blind, placebo-controlled study on effective treatment for CFS/fibromyalgia was published in the Journal of Chronic Fatigue Syndrome (8:2,2001).

That research found a 90% improvement in quality of life among 91% of patients with CFS using a comprehensive treatment protocol called S.H.I.N.E. He has also completed 3 more recent studies on effective treatment of post-viral CFS. "The downside is that even if researchers discover an effective and safe pharmaceutical treatment for long COVID, it won't be FDA-approved and available to the millions who will need it for at least a decade, probably two.

The Warp Speed solution that's already available is the S.H.I.N.E. protocol, which has helped thousands with CFS/fibromyalgia over the past 20+ years." Please let me know if you'd like to speak to Dr. Teitelbaum about the crossover between long COVID and Chronic Fatigue Syndrome and how S.H.I.N.E. could be implemented effectively on a national scale.

-----------

About Dr. Dean Fanelli
Dean Fanelli, Ph.D. is a patent, regulatory, and transactional attorney in the Washington, DC office of Cooley LLP (www.cooley.com) focusing on issues related to the development, protection, and commercialization of biotech and pharmaceutical products. In addition to Dr. Fanelli's expertise relating to legal issues involved in pharma and biotech development, Dr. Fanelli also understands the business needs of his clients as he has co-founded three biotechnology companies: PhosImmune, Inc. an immuno-oncology company, C-Reveal Therapeutics, LLC, an immuno-oncology drug development company focused on exposing tumors to immune responses and therapies, and most recently AexeRNA Therapeutics, LLC, an mRNA company developing advanced Lipid Nanoparticle delivery systems that reduce the side effects present in currently authorized mRNA COVID-19 vaccines. He is a regular on TV & Radio commenting on Covid-19 & Vaccines & also hosts his own podcast “Politics & Life Sciences Radio.”